Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
Authors:
- Andreas JekleAJAndreas Jekle
- Santosh Kumar ThatikondaSTSantosh Kumar Thatikonda
- Ruchika JaisinghaniRJRuchika Jaisinghani
- Suping RenSRSuping Ren
- April KinkadeAKApril Kinkade
- Sarah K. StevensSSSarah K. Stevens
- Antitsa StoychevaASAntitsa Stoycheva
- Vivek K. RajwanshiVRVivek K. Rajwanshi
- Caroline WilliamsCWCaroline Williams
- Jerome DevalJDJerome Deval
- Qingling ZhangQZQingling Zhang
Open Access
- 13 November 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16274
Abstract
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking the innate and acquired immune systems. First-generation STING agonists are administered intratumorally; however, a systemic delivery route would greatly expand the clinical use of STING agonists. Biochemical and cell-based experiments, as well as syngeneic mouse efficacy models, were used to demonstrate the anti-tumoral activity of ALG-031048, a novel STING agonist. In vitro, ALG-031048 is highly stable in plasma and liver microsomes and is resistant to degradation via phosphodiesterases. The high stability in biological matrices translated to good cellular potency in a HEK 293 STING R232 reporter assay, efficient activation and maturation of primary human dendritic cells and monocytes, as well as long-lasting, antigen-specific anti-tumor activity in up to 90% of animals in the CT26 mouse colon carcinoma model. Significant reductions in tumor growth were observed in two syngeneic mouse tumor models following subcutaneous administration. Combinations of ALG-031048 and ICIs further enhanced the in vivo anti-tumor activity. This initial demonstration of anti-tumor activity after systemic administration of ALG-031048 warrants further investigation, while the combination of systemically administered ALG-031048 with ICIs offers an attractive approach to overcome key limitations of ICIs in the clinic.Keywords
Funding Information
- Aligos Therapeutics
This publication has 30 references indexed in Scilit:
- Design of amidobenzimidazole STING receptor agonists with systemic activityNature, 2018
- Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1Nature Communications, 2018
- Enhancing immunotherapy of STING agonist for lymphoma in preclinical modelsBlood Advances, 2018
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of CancerClinical Cancer Research, 2015
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Reports, 2015
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic TumorsImmunity, 2014
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic TumorsImmunity, 2014
- Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogsNature Chemical Biology, 2014
- STING-dependent cytosolic DNA sensing pathwaysTrends in Immunology, 2014
- The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STINGCell Reports, 2013